# Neurona Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurona-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.neuronatherapeutics.com
- Total disclosed funding: $284M
- Latest round: Series F (Mar 28, 2025)
- Investors on record: 19

## About

Based in California, US, and founded in 2008 by co-founder and CEO Cory R. Nicholas, Neurona Therapeutics, Inc. is a clinical-stage biotherapeutics company that focuses on the development of cell-based therapeutics and treatment devices for neurological diseases and disorders. The company raised venture funding from Ysios Capital Partners. In April 2025, Neurona Therapeutics Inc. raised USD 102 million in venture funding from Fidelity Investments, YK Bioventures, Soleus Capital, Spur Capital Partners, Alexandria Venture Investments, Ysios Capital Partners, UC Ventures, Berkeley Frontier Fund, Willett Advisors, UCB Ventures, Euclidean Capital, LYFE Capital, Schroders Capital, Cormorant Asset Management, Viking Global Investors, The Column Group, and other unspecified investors. The company specializes in developing neural cell therapies for chronic neurological disorders. The company’s primary product, NRTX-1001, consists of inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001 is also being studied for its potential benefits in Alzheimer's disease by repairing neural activity and improving cognition. This therapy addresses drug-resistant focal epilepsy by enhancing GABAergic inhibition to reduce seizure activity.  The company will use the April 2025 funding to advance its wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE).

## Funding rounds

- Series F, Mar 28, 2025, $102M — Schroders Capital, Spur Capital, Alexandria Venture Investments, The Column Group, Viking Global Investors, Ysios Capital Partners, Fidelity Investments, Willett Advisors, Cormorant Asset Management, UC Ventures, LYFE Capital, Euclidean Capital, UCB Ventures, Soleus Capital, Berkeley Frontier Fund, YK Bioventures
- Series E, Feb 6, 2024, $120M — Schroders Capital, Spur Capital, Alexandria Venture Investments, The Column Group, Viking Global Investors, Ysios Capital Partners, Willett Advisors, Sphera Fund Management, Cormorant Asset Management, UC Ventures, LYFE Capital, Euclidean Capital, UCB Ventures, SymBiosis Capital Management, Berkeley Frontier Fund
- Series D, Jun 22, 2021, $42M — Alexandria Venture Investments, The Column Group, Sphera Fund Management, Ironfire Ventures, UCB Ventures
- Series A, Dec 28, 2016, $21M — The Column Group

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series D, Series E, Series F
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series D, Series E, Series F
- Sphera Fund Management — Series D, Series E
- Ironfire Ventures (https://capitalatlas.ai/funds/ironfire-ventures) — Series D
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series D, Series E, Series F
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series E, Series F
- Spur Capital (https://capitalatlas.ai/funds/spur-capital) — Series E, Series F
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series E, Series F
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series E, Series F
- Willett Advisors — Series E, Series F
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series E, Series F
- UC Ventures (https://capitalatlas.ai/funds/uc-ventures) — Series E, Series F
- LYFE Capital — Series E, Series F
- Euclidean Capital — Series E, Series F
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series E
- Berkeley Frontier Fund (https://capitalatlas.ai/funds/berkeley-frontier-fund) — Series E, Series F
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series F
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series F
- YK Bioventures (https://capitalatlas.ai/funds/yk-bioventures) — Series F